Grace Therapeutics, Inc. (GRCE)
Grace Therapeutics, Inc. (GRCE) from its SEC filings: 2021 revenue $100.0 million, net margin -10%, free cash flow -$17.2 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2021) | $100.0 million |
| Net income | -$9.8 million |
| Net margin | -9.8% |
| Free cash flow | -$17.2 million |
| Diluted EPS | $-0.27 |
| Latest quarter (Q4 2021 (calendar)) revenue vs a year earlier | -100% |
| Cash | $13.8 million |
| Share count, 1 year | +52% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-21. Education only, not financial advice.